We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Laser-Based Imaging Technique Enables Much Faster Tissue Diagnosis during Tumor Surgery

By LabMedica International staff writers
Posted on 26 Oct 2023
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)

The central nervous system can have around 120 different kinds of tumors, and the first step in treating them generally involves surgery along with acquiring histological samples. During this procedure, a small part of the tumor is excised and a histological frozen section is readied in the neuropathology department to better understand the tumor's features. Now, a newly developed laser-based imaging method allows neuropathologists to generate a report in just a matter of minutes.

Surgeons at Medical University Vienna (Vienna, Austria) have started employing this novel laser-based imaging method that considerably speeds up tissue diagnosis during tumor surgeries. Using Stimulated Raman Histology (SRH), a digital cross-section of the tissue can be instantly created right in the surgical suite, enabling a diagnosis within just a few minutes. In comparison, the standard method involving tissue transportation, manual preparation, and analysis usually takes around 30 minutes on an international average.

One of the advantages of this technique is that since the tissue is examined in its natural, untreated form, it remains fully available for any subsequent, more in-depth diagnostic tests. If SRH detects diagnostic tumor tissue, needle biopsies can also be concluded much more quickly. These procedures are not applicable just to brain tumors but can also be utilized for confirming diagnoses of other neurological conditions like blood vessel inflammatory diseases and demyelinating lesions. Initially developed in the United States, the SRH method was first adopted in Europe at the Department of Neurosurgery of MedUni Vienna and University Hospital Vienna, led by Georg Widhalm. A research study at MedUni Vienna showed a 99% correlation between digital histology and conventional frozen section.

"The new technology enables surgeons to make faster decisions regarding the optimal surgical strategy in the operating room, which significantly reduces the time in the operating room for patients. In addition, the safety of the procedure is also increased," said Georg Widhalm.

Related Links:
Medical University Vienna 

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more